These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34557502)

  • 1. Topical Application of the PI3Kβ-Selective Small Molecule Inhibitor TGX-221 Is an Effective Treatment Option for Experimental Epidermolysis Bullosa Acquisita.
    Zillikens H; Kasprick A; Osterloh C; Gross N; Radziewitz M; Hass C; Hartmann V; Behnen-Härer M; Ernst N; Boch K; Vidarsson G; Visser R; Laskay T; Yu X; Petersen F; Ludwig RJ; Bieber K
    Front Med (Lausanne); 2021; 8():713312. PubMed ID: 34557502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita.
    Koga H; Kasprick A; López R; Aulí M; Pont M; Godessart N; Zillikens D; Bieber K; Ludwig RJ; Balagué C
    Front Immunol; 2018; 9():1558. PubMed ID: 30050528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita.
    Haeger SC; Kridin K; Pieper M; Griewahn L; Nimmerjahn F; Zillikens D; König P; Ludwig RJ; Hundt JE
    Front Immunol; 2022; 13():938306. PubMed ID: 36311755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases.
    Ghorbanalipoor S; Emtenani S; Parker M; Kamaguchi M; Osterloh C; Pigors M; Gross N; Khil'chenko S; Kasprick A; Patzelt S; Wortmann D; Ibrahim IO; Izumi K; Goletz S; Boch K; Kalies K; Bieber K; Smith P; Schmidt E; Ludwig RJ
    Front Immunol; 2022; 13():865241. PubMed ID: 36248903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model systems duplicating epidermolysis bullosa acquisita: a methodological review.
    Ludwig RJ
    Autoimmunity; 2012 Feb; 45(1):102-10. PubMed ID: 21923614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fcγ Receptor IIB Controls Skin Inflammation in an Active Model of Epidermolysis Bullosa Acquisita.
    Kovacs B; Tillmann J; Freund LC; Nimmerjahn F; Sadik CD; Bieber K; Ludwig RJ; Karsten CM; Köhl J
    Front Immunol; 2019; 10():3012. PubMed ID: 31993051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventive but Not Therapeutic Topical Application of Local Anesthetics Can Inhibit Experimental Epidermolysis Bullosa Acquisita in Mice.
    Wen L; Dong X; Li Q; Schramm G; Zhang B; Zillikens D; Ludwig RJ; Petersen F; Yu X
    Front Immunol; 2021; 12():750160. PubMed ID: 34712239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune mechanism-targeted treatment of experimental epidermolysis bullosa acquisita.
    Ludwig R
    Expert Rev Clin Immunol; 2015; 11(12):1365-78. PubMed ID: 26471717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosensitive Hematopoietic Cells Determine the Extent of Skin Inflammation in Experimental Epidermolysis Bullosa Acquisita.
    Iwata H; Witte M; Samavedam UK; Gupta Y; Shimizu A; Ishiko A; Schröder T; Seeger K; Dahlke M; Rades D; Zillikens D; Ludwig RJ
    J Immunol; 2015 Sep; 195(5):1945-54. PubMed ID: 26202985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDE4 Inhibition as Potential Treatment of Epidermolysis Bullosa Acquisita.
    Koga H; Recke A; Vidarsson G; Pas HH; Jonkman MF; Hashimoto T; Kasprick A; Ghorbanalipoor S; Tenor H; Zillikens D; Ludwig RJ
    J Invest Dermatol; 2016 Nov; 136(11):2211-2220. PubMed ID: 27388992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luteolin peracetate and gossypolone inhibit immune complex-mediated neutrophil activation
    Yang K; Yin J; Yue X; Bieber K; Riemekasten G; Ludwig RJ; Petersen F; Yu X
    Front Immunol; 2023; 14():1196116. PubMed ID: 37720234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The retinoid-related orphan receptor alpha is essential for the end-stage effector phase of experimental epidermolysis bullosa acquisita.
    Sadeghi H; Gupta Y; Möller S; Samavedam UK; Behnen M; Kasprick A; Bieber K; Müller S; Kalies K; de Castro Marques A; Recke A; Schmidt E; Zillikens D; Laskay T; Mariani J; Ibrahim SM; Ludwig RJ
    J Pathol; 2015 Sep; 237(1):111-22. PubMed ID: 25953430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cells, dendritic cells, and macrophages are required to induce an autoreactive CD4 helper T cell response in experimental epidermolysis bullosa acquisita.
    Iwata H; Bieber K; Tiburzy B; Chrobok N; Kalies K; Shimizu A; Leineweber S; Ishiko A; Vorobyev A; Zillikens D; Köhl J; Westermann J; Seeger K; Manz R; Ludwig RJ
    J Immunol; 2013 Sep; 191(6):2978-88. PubMed ID: 23960233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of epidermolysis bullosa acquisita, an autoimmune subepidermal bullous disease.
    Hashimoto T; Ishii N; Ohata C; Furumura M
    J Pathol; 2012 Sep; 228(1):1-7. PubMed ID: 22692770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Propranolol Off-Target: A New Therapeutic Option in Neutrophil-Dependent Dermatoses?
    Maglie R; Solimani F; Quintarelli L; Hertl M
    J Invest Dermatol; 2020 Dec; 140(12):2326-2329. PubMed ID: 33222759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita.
    Ludwig RJ
    ISRN Dermatol; 2013; 2013():812029. PubMed ID: 23956869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signalling and targeted therapy of inflammatory cells in epidermolysis bullosa acquisita.
    Ludwig RJ
    Exp Dermatol; 2017 Dec; 26(12):1179-1186. PubMed ID: 28266741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of antibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita.
    Ludwig RJ; Recke A; Bieber K; Müller S; Marques Ade C; Banczyk D; Hirose M; Kasperkiewicz M; Ishii N; Schmidt E; Westermann J; Zillikens D; Ibrahim SM
    J Invest Dermatol; 2011 Jan; 131(1):167-76. PubMed ID: 20720563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of anti-type VII collagen IgE antibodies in epidermolysis bullosa acquisita.
    Koga H; Teye K; Yamashita K; Ishii N; Tsuruta D; Nakama T
    Br J Dermatol; 2019 May; 180(5):1107-1113. PubMed ID: 30311191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat shock protein 90 is required for ex vivo neutrophil-driven autoantibody-induced tissue damage in experimental epidermolysis bullosa acquisita.
    Tukaj S; Hellberg L; Ueck C; Hänsel M; Samavedam U; Zillikens D; Ludwig RJ; Laskay T; Kasperkiewicz M
    Exp Dermatol; 2015 Jun; 24(6):471-3. PubMed ID: 25739426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.